Sign in to NCBI
Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy.

Pierrillas PB, Henin E, Ball K, Ogier J, Amiel M, Kraus-Berthier L, Chenel M, Bouzom F, Tod M.

Drug Metab Dispos. 2019 Jun;47(6):648-656. doi: 10.1124/dmd.118.085605. Epub 2019 Apr 2.

PMID:
30940629

Similar articles

2.

Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice.

Pierrillas PB, Henin E, Ogier J, Kraus-Berthier L, Chenel M, Bouzom F, Tod M.

J Pharmacol Exp Ther. 2018 Dec;367(3):414-424. doi: 10.1124/jpet.118.251694. Epub 2018 Sep 18.

PMID:
30228112

Similar articles

3.

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.

Shebley M, Sandhu P, Emami Riedmaier A, Jamei M, Narayanan R, Patel A, Peters SA, Reddy VP, Zheng M, de Zwart L, Beneton M, Bouzom F, Chen J, Chen Y, Cleary Y, Collins C, Dickinson GL, Djebli N, Einolf HJ, Gardner I, Huth F, Kazmi F, Khalil F, Lin J, Odinecs A, Patel C, Rong H, Schuck E, Sharma P, Wu SP, Xu Y, Yamazaki S, Yoshida K, Rowland M.

Clin Pharmacol Ther. 2018 Jul;104(1):88-110. doi: 10.1002/cpt.1013. Epub 2018 Feb 2. Review.

PMID:
29315504
Free PMC Article

Similar articles

4.

Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions.

Nicolas JM, Bouzom F, Hugues C, Ungell AL.

Biopharm Drug Dispos. 2017 Apr;38(3):209-230. doi: 10.1002/bdd.2052. Epub 2017 Feb 6. Review.

PMID:
27976409
Free PMC Article

Similar articles

5.

Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.

Peigné S, Bouzom F, Brendel K, Gesson C, Fouliard S, Chenel M.

J Pharmacokinet Pharmacodyn. 2016 Feb;43(1):13-27. doi: 10.1007/s10928-015-9451-z. Epub 2015 Nov 12.

PMID:
26563503

Similar articles

6.

Physiologically Based Models in Regulatory Submissions: Output From the ABPI/MHRA Forum on Physiologically Based Modeling and Simulation.

Shepard T, Scott G, Cole S, Nordmark A, Bouzom F.

CPT Pharmacometrics Syst Pharmacol. 2015 Apr;4(4):221-5. doi: 10.1002/psp4.30. Epub 2015 Apr 2.

PMID:
26225245
Free PMC Article

Similar articles

7.

Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human.

Ball K, Bouzom F, Scherrmann JM, Walther B, Declèves X.

Biopharm Drug Dispos. 2014 Nov;35(8):485-99. doi: 10.1002/bdd.1908. Epub 2014 Sep 17.

PMID:
25044007

Similar articles

8.

A physiologically based modeling strategy during preclinical CNS drug development.

Ball K, Bouzom F, Scherrmann JM, Walther B, Declèves X.

Mol Pharm. 2014 Mar 3;11(3):836-48. doi: 10.1021/mp400533q. Epub 2014 Jan 29.

PMID:
24446829

Similar articles

9.

S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.

Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Léonce S, Ferry G, Da Violante G, Bouzom F, Cattan V, Jacquet-Bescond A, Comoglio PM, Lockhart BP, Boutin JA, Cordi A, Ortuno JC, Pierré A, Hickman JA, Cruzalegui FH, Depil S.

Mol Cancer Ther. 2013 Sep;12(9):1749-62. doi: 10.1158/1535-7163.MCT-13-0075. Epub 2013 Jun 26.

PMID:
23804704
Free Article

Similar articles

10.

Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Ball K, Bouzom F, Scherrmann JM, Walther B, Declèves X.

AAPS J. 2013 Oct;15(4):913-32. doi: 10.1208/s12248-013-9496-0. Epub 2013 Jun 20. Review.

PMID:
23784110
Free PMC Article

Similar articles

11.

Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone.

Ball K, Bouzom F, Scherrmann JM, Walther B, Declèves X.

J Pharm Sci. 2012 Nov;101(11):4277-92. doi: 10.1002/jps.23266. Epub 2012 Aug 1.

PMID:
22864977

Similar articles

12.

Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as normalization factor.

Hamm G, Bonnel D, Legouffe R, Pamelard F, Delbos JM, Bouzom F, Stauber J.

J Proteomics. 2012 Aug 30;75(16):4952-4961. doi: 10.1016/j.jprot.2012.07.035. Epub 2012 Jul 26.

PMID:
22842155

Similar articles

13.

Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?

Bouzom F, Ball K, Perdaems N, Walther B.

Biopharm Drug Dispos. 2012 Mar;33(2):55-71. doi: 10.1002/bdd.1767. Epub 2012 Jan 26. Review.

PMID:
22228149

Similar articles

14.

Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.

Bruyère A, Declèves X, Bouzom F, Ball K, Marques C, Treton X, Pocard M, Valleur P, Bouhnik Y, Panis Y, Scherrmann JM, Mouly S.

Mol Pharm. 2010 Oct 4;7(5):1596-607. doi: 10.1021/mp100015x. Epub 2010 Aug 4.

PMID:
20604570

Similar articles

15.

Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.

Perdaems N, Blasco H, Vinson C, Chenel M, Whalley S, Cazade F, Bouzom F.

Clin Pharmacokinet. 2010 Apr;49(4):239-58. doi: 10.2165/11318130-000000000-00000.

PMID:
20214408

Similar articles

16.

Development of an optimized procedure for the preparation of rat intestinal microsomes: comparison of hepatic and intestinal microsomal cytochrome P450 enzyme activities in two rat strains.

Bruyère A, Declevès X, Bouzom F, Proust L, Martinet M, Walther B, Parmentier Y.

Xenobiotica. 2009 Jan;39(1):22-32. doi: 10.1080/00498250802517714 .

PMID:
19219745

Similar articles

17.

Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.

Chenel M, Bouzom F, Aarons L, Ogungbenro K.

J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):635-59. doi: 10.1007/s10928-008-9104-6. Epub 2009 Jan 7.

PMID:
19130188

Similar articles

18.

Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.

Chenel M, Bouzom F, Cazade F, Ogungbenro K, Aarons L, Mentré F.

J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):661-81. doi: 10.1007/s10928-008-9105-5. Epub 2009 Jan 7.

PMID:
19130187
Free PMC Article

Similar articles

19.

Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling.

Bouzom F, Walther B.

Fundam Clin Pharmacol. 2008 Dec;22(6):579-87. doi: 10.1111/j.1472-8206.2008.00648.x. Review.

PMID:
19049658

Similar articles

20.

Use of nonlinear mixed effect modeling for the meta-analysis of preclinical pharmacokinetic data: application to S 20342 in the rat.

Bouzom F, Laveille C, Merdjan H, Jochemsen R.

J Pharm Sci. 2000 May;89(5):603-13.

PMID:
10756326

Similar articles

21.

S 12340: a potent inhibitor of the oxidative modification of low-density lipoprotein in vitro and ex vivo in WHHL rabbits.

Breugnot C, Privat S, Guillonneau C, Regnier G, Bouzom F, Vilaine JP, Lenaers A.

J Pharmacol Exp Ther. 1994 May;269(2):515-20.

PMID:
8182520

Similar articles

Supplemental Content

Filters: Manage Filters

Loading ...
You are here: NCBI > Literature > PubMed
Support Center